Skip to Main Content

INFORMATION FOR

Research Grants

Sanjay Aneja

Past Grants

Agency Grant Name Agency Number
AHRQ Yale-CORE Career Development Program in Patient-Centered Outcomes Research 5 K12 HS023000
MedNet, Inc. (NSF/SBIR) An Online Peer-to-Peer Resource for Oncologists to Improve Clinical Trial Knowledge and Enrollment
American Cancer Society-Institutional Research Grant Deriving Imaging Based Biomarkers for Brain Metastases Using Deep Learning
Yale SPORE in Lung Cancer Development Research Program Deriving Imaging Based Biomarkers for Non-Small Lung Cancer Using Deep Learning

Current Grants

Agency Grant Name Agency Number
Conquer Cancer/The ASCO Foundation Deriving Imaging-Based Biomarkers for Non-Small Cell Lung Cancer Patients Using Deep Learning
University of Iowa/NSF Convergence Accelerator NSF Convergence Accelerator - Track D: ImagiQ: Asynchronous and Decentralized Federated Learning for Medical Imaging
Robert E. Leet and Clara Guthrie Patterson Trust, Mentored Research Award Deriving Imaging Based Biomarkers for Non-Small Cell Lung Cancer Using Deep Learning
Yale SPORE in Lung Cancer Development Research Program Implementation of Deep Learning Derived Imaging Based Biomarkers for Non-Small Lung Cancer

Ranjit Bindra

Past Grants

Agency Grant Name Agency Number
Lion Heart Fund Exploiting HR defects in Breast Cancer with DNA-PK Inhibitor-Based Therapies
NIH/NICHD Drug delivery system for enhancing radiation therapy in pediatric glioma R21 HD090503
Cybrexa Therapeutics In vivo validation of peptide-drug conjugates
The Hope Foundation/SWOG Identification and characterization of oncometabolite-induced DNA repair defects in sporadic papillary kidney cancer
CureSearch for Children’s Cancer Exploiting Mutant IDH1/2-induced DNA Repair Defects in Pediatric Glioma
Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF) Small-molecule Screening for Novel Pediatric Glioma Radiosensitizers
YCCI Just-in time Small Pilot Grants Utilizing Core Technologies Development of Novel Methods to Assess DNA Repair Status in Primary Cell Culture Using Next Generation Sequencing
Joanna McAfee Childhood Cancer Foundation Creation of Inducible PAX3/7- FOXO1 Cell Lines for Synthetic Lethal Screening Studies
YCC Pilot High-throughput Screening for K-ras Mutant Cell Tumor Radiosensitizers
YCCC T-TARE DNA Damage Response: The Achilles Heel of HPV-associated HNSCC
The Cure Starts Now/DIPG Collaborative Pre-clinical Development of Novel DIPG Radiosensitizers
Matthew Larson Foundation Creation of Isogenic Pediatric Glioma Cell Lines for High-Throughput Drug Screening Campaigns
NIH/NCI Development of a Novel Assay to Measure DSB Repair at Endogenous Loci in Cells 1 R03 CA194967-01
Yale SPORE in Lung Cancer High-throughput screening for K-Ras mutant tumor cell radiosensitizers
American Cancer Society-Research Scholar Grant Pre-clinical Development of Mibefradil as a Novel Glioma Radiosensitizer 128352-RSG-15-197-01-TBG
Yale Cancer Center Nanoparticle-Encapsulated Radiosensitizers for the Treatment of Glioblastoma Multiforme
Musella Foundation Nanoparticle-Encapsulated Radiosensitizers for the Treatment of Glioblastoma Multiforme
The Pablove Foundation Small Molecule Screening for Novel Rhabdoid Tumor Inhibitors
Yale Cancer Center 2017- co- Pilot Exploitation of 2-HG conferred vulnerabilities in IDH1/2 mutant MDS/AML in pre-clinical PDX models
Alex’s Lemonade Stand Foundation – Innovation Award Development of nanoparticle-encapsulated chemo/radio-sensitizers for intrathecal delivery
Leukemia and lymphoma Society – Translational Research Program Exploiting mutant IDH1/2-induced BRCAness with PARP inhibitors as a novel AML/MDS therapy
YCC - 2019 Co-Pilot Development of Nanoparticle-Encapsulated NAMPT inhibitors to target PPM1D-mutant DIPG
NIH/SBIR Development of tumor-targeted PARP inhibitors for the treatment of solid cancers R44CA236107
Cybrexa, Inc. 2019 Sponsored Research Agreement
UCLA/The Hope Foundation for Cancer Research Identification and characterization of oncometabolite-induced DNA repair defects in sporadic papillary kidney cancer
T-TARE/Yale Brain Tumor Translational Program Molecular Correlates of PARP Inhibitor Response and Target Engagement in a Bench-to-Bedside IDH1/2-mutant Glioma Phase I/II Clinical Trial
Oligo Nation/Cure Targeting IDH1/2-mutant gliomas with the potent, CNS-permeable PARP inhibitor, BGB-290
The Cure Starts Now/DIPG Collaborative Pre-clinical Development of Novel DIPG Radiosensitizers
NIH/NCI Exploiting Mutant IDH1/2-Induced Homologous Recombination Defects in Cancer RO1 CA215453
Rising Tide Foundation Phase 2 Study of the PARP Inhibitor Olaparib in IDH1/2-mutant solid tumors
Yale Cancer Center/Yale Discovery Fund Beyond the BBB: Exploiting NAD metabolic defects in glioma using CNS-directed nanoparticles

Current Grants

Agency Grant Name Agency Number
Blavatnik Fund for Innovation at Yale Athena Therapeutic - Targeting cancer at is core
National Brain Tumor Society Developing novel drug combinations which target meta-states in IDH1/2-mutant glioma
Andrew McDonough B+ Foundation Exploiting NAD Metabolism Defects in Pediatric Brian Tumors
Athena Therapeutics, LLC Athena/Yale Sponsored Research Agreement
Syros Pharmaceuticals, Inc. Focused Synthetic Lethal Screening for CDK12 inhibitor interactions
National Brain Tumor Society Project TDG: Targeting the DDR in Glioblastoma
Aztek Bio, LLC Aztek/Yale Sponsored Research Agreement
Gateway for Cancer Research Exploiting mutant IDH1/2-induced DNA repair defects in a Phase I/II clinical trial
NIH/NCI Targeting Defective DNA Damage Response Pathways in IDH1/2- mutant AML RO1CA266604
Mayo Clinic/NIH/NCI Center of Innovation of Brain Tumor Therapeutics U19CA264362

Douglas Brash

Past Grants

Agency Grant Name Agency Number
DOD UVL, ROS, Pigmentation, Genetic Predisposition, and Epigenetic Gene Silencing in Melanoma W81XWH-10-1-0629
L'Oreal Controlling Chemiexcitation in the Skin: Exploration of Dark CPD Production in Skin
Leo Foundation Chemiexcitation in Human Disease

Current Grants

Agency Grant Name Agency Number
NIH Yale SPORE in Skin Cancer 2 P50 CA121674-07
NIH/NIAMS Chemiexcitation: A New Mode of Skin Disease R01 AR070851
NIH/NIEHS Applying Genomic Dosimeters of UV Damage to Predicting Skin Cancer Risk R01 ES030562
NIH/NCI Using Clonal and Non-Clonal UV Signature Mutations to Predict Skin Cancer Risk R01 CA240602

Zhe Chen

Past Grants

Agency Grant Name Agency Number
NCI Prostate Edema in Permanent Interstitial Brachytherapy 5 R01 CA134627-03

Joseph Contessa

Past Grants

Agency Grant Name Agency Number
NIH/NIAID Targeting STT3A and STT3B to Block Flavivirus Replication R41 AI134531
ASTRO Targeting N-Linked Glycosylation to Radiosensitive Malignant Gliomas
YCCI EGFT: Therapeutic Target and Biomarker in NSCLC 5 UL1 RR024139-05
NIH A Bioluminescent Screen for Inhibitors of N-linked Glycosylation 5 R03 DA033178-02
American Cancer Society Institutional Grant Targeting N-linked Glycosylation in Non-Small Cell Lung Cancer ACS #IRG-58-012-56
American Cancer Society Research Scholar Grant Targeting N-linked Glycosylation in Non-Small Cell Lung Cancer
NIH Targeted N-linked Glycosylation to Advance Radiation Therapy 1 R01 CA172391-01A1
NIH Validation of Quantitative 11C-Erlotinib PET for Imaging EGFR-Mutant Lung Cancer 1 R01 CA195493-01
Department of Defense Small Molecule Inhibition of the Oligosaccharyltransferase for the Treatment of Breast Cancer W81XWH-17-1-0066
NIH/NIGMS Regulation of N-linked Glycosylation in Mammalian Cells R01 GM127383
YCC – Innovation Award Targeting TRIM16 Mutations in Osteosarcoma
YCC – 2019 Pilot Genetic Screens for HNSSC Radiosensitivity
Spring Bank Pharmaceuticals, Inc. Spring Bank Pharmaceuticals Sponsored Research Agreement

Current Grants

Agency Grant Name Agency Number
Yale Cancer Center/Yale Discovery Fund STING: Biomarker and Therapeutic Target in HNSCC R01GM127383
NIH/NCI OST Inhibition in NSCLC R01CA240418
Emerson Collective, Proof of Concept Venture Fund Oligosaccharyltransferase Inhibitors for the Treatment of NSCLC
Harrington Discovery Institute Oligosaccharyltransferase Inhibitors for the Treatment of NSCLC
Blavatnik Fund for Innovation at Yale Apira: Developing Therapeutic OST Inhibitors
Yale Cancer Center Team Challenge

Crosstalk between nuclear and genome integrity in dictating the response to cancer therapy

Project 3: Regulation of DNA Repair and Genome Integrity by JAK1 signaling

NIH/NCI Small Animal Radiation Research Platform (SARRP) for Yale University 1S10 OD 030493-01A1

Roy Decker

Current Grants

Agency Grant Name Agency Number
Merck Evaluation of Vorinostat in Combination with Palliative Radiotherapy for Patients with Stage IV Non-small Cell Lung Cancer 1 35468
RTOG-Clinical Study Radiation Therapy Oncology Group 1 U10-CA21661
SciClone Pharmaceuticals, Inc. A Phase 2b, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07
NIH/NCI Yale Cancer Center NCTN LAPS UG1CA233337
Oregon Health Science University/NIH/NCI SWOG Network Group Operations Center of the NTCN U10CA180888

Jun Deng

Past Grants

Agency Grant Name Agency Number
NIH/NIBIB Tracking Organ Doses for Patient Safety in Radiation Therapy 1 R01 EB022589-01
National Science Foundation A generalizable data framework towards precision radiotherapy 1918925 DMS/NLM
University of South Carolina/Leidos Dynamic Multiscale Digital Twin for a Lung Cancer Patient
University of South Carolina/DOS Dynamic Multiscale Digital Twin for a Lung Cancer Patient

Luisa Escobar-Hoyos

Past Grants

Agency Grant Name Agency Number
Hirshberg Foundation for Pancreatic Cancer Understanding and targeting a novel mutant p53 Kras cooperation mechanism in pancreatic cancer
Yale SPORE in Lung Cancer, Development Research Program Award Understanding and targeting altered RNA splicing in treatment-resistant lung tumors
Yale SPORE in Lung Cancer, Career Enhancement Program RNA splicing as a novel therapeutic target in lung cancers
Yale Cancer Center, Pilot Restoring anti-tumor immunity by correcting RNA splicing defects in T cells
Yale SPORE in Lung Cancer, Career Enhancement Program RNA splicing as a novel therapeutic target in lung cancers with mutant p53

Current Grants

Agency Grant Name Agency Number
NIH/NCI Altered mRNA splicing dependent on mutant p53 identifies novel therapeutic vulnerability in pancreatic cancer R00CA226342
Damon Runyon Cancer Research Foundation, Innovation Award Understanding RNA splicing in tumor-cell adaptation and anti-tumor immunity
AACR - Ruth Bader Ginsberg RNA splicing: The missing link in pancreatic cancer pathogenesis & immunity
NIH/NCI Unleashing T-cell anti-tumor response through repair of altered RNA splicing and antigen mimicry recognition 1DP2CA280625-01

Peter Glazer

Past Grants

Agency Grant Name Agency Number
NIH Cancer Center Support Grant (CCSG) P30 CA016359-37
NIH Cell-Penetrating Anti-DNA Antibody for Radiosensitization and Cancer Therapy 5 R01 CA168733-05
NIH Bifunctional Antibodies for Melanoma Therapy 5 RO1 CA177719-03
NIH In Vivo Genomic Editing of Hematopoietic Cells for HIV Resistance 5 R01 AI112443-02
NIH Targeted Correction of the Human CFTR Gene 5 R01 HL125892-02
Cystic Fibrosis Foundation Therapeutics Gene Editing Using Nanoparticles with Triplex-Forming PNAs EGAN15XXO
PNA Innovations, Inc Modified PNAs To Develop Gene Editing Therapeutics for Hematopoietic Blood Disorders and Cystic Fibrosis Sponsored Research Award
amfAR, The Foundation for AIDs Research Targeted Inactivation of Integrated HIV Through Host Cell DNA Repair Pathways Investment Grant
FARF Use of Triplex-Forming PNAs as a Strategy for Correction of the FA Phenotype Fanconi Anemia Research Fund Award
Rett Syndrome Research Trust PNA Nanoparticles for Gene Editing in Rett Syndrome
Medical College of Wisconsin/NIH/NHGRI Non-enyzmatic Gene Editing in Nonhuman Primates by Next Generation PNA Nanoparticles
Medical College of Wisconsin/NIH/NHGRI Development of a GFP-IVS2 Mouse Reporter Strain for PNA-based Genome Editing Detection

Current Grants

Agency Grant Name Agency Number
NIH Hypoxia, DNA Repair and Gene Silencing 5 R01 ES005775-24
NIH Yale Cancer Biology Training Grant 5 T32CA193200-02
NIH/NCI Novel DNA Repair Inhibitors for Cancer Therapy R35 CA197574-01A1
NIH/NHLBI Poly(amine-co-ester)s for Targeted Delivery In Vivo of Gene Editing Agents to Bone Marrow and Lung UG3 HL147352
NIH/NHLBI Nonenzymatic Gene Editing in Treatment of Heredity Spherocytosis R01 HL139756
Cystic Fibrosis Foundation Targeted Correction of W1282X-CFTR
NIH/NIAID PNA Nanoparticles for Gene Editing In Vivo U01 AI145965
Blavatnik Fund for Innovation at Yale Antibody meditated Gene Delivery & Editing
Gennao Bio, LLC A Novel Antibody for Targeted Nucleic Acid Delivery for Skeletal Muscle, Oncology, CNS and Gene Therapy Indications
J. David Gladstone Institutes/NIH/NIAID Hope - HIV Obstruction by Programmed Epigenetics UM1 Al164559

James Hansen

Past Grants

Agency Grant Name Agency Number
Radiological Society of North America (RSNA) Targeting Cancer with Cell Penetrating Anti-DNA Antibody RR1108
American Cancer Society Institutional Grant Investigating Lupus Autoantibody-based Cancer Therapy ACS-IRG #58-012-55
RSNA -Research Scholar Grant Targeting Glioblastoma with a Lupus Autoantibody
YCC 2014 Pilot Targeting KRAS Mutant Cancer Cells with a Lupus Anti-guanosine Antibody
YCCI 2014 Scholar Grant Targeting Cancer with a Lupus Autoantibody
Lion Heart Cancer Research Fund Deoxymab: A Targeted Biologic that is Synthetically Lethal to Triple-Negative Breast Cancer Brain Metastases

Current Grants

Agency Grant Name Agency Number
Patrys Limited Deoxymab for Cancer Therapy
Department of Defense – BCRP Targeting breast cancer brain metastases with an anti-DNA autoantibody WE1XWH191049
NIH/NINDS Targeting Glioblastoma with a Nuclear-Penetrating Anti-DNA Autoantibody R01NS112223

Thomas Hayman

Past Grants

Agency Grant Name Agency Number
Yale Cancer Center, K12 Immuno-Oncology Training Program STING and the DNA Damage Response in Head and Neck Squamous Cell Carcinoma
Yale Head and Neck SPORE, Career Enhancement Program STING-Dependent Regulation of the Tumor-Intrinsic DNA-Damage Response in Head and Neck Squamous Cell Carcinoma
Yale SPORE in Lung Cancer, Career Enhancement PLK4 Inhibition as a Strategy to Enhance the Non-Small Cell Lung Cancer Radiation Response

Ryan Jensen

Past Grants

Agency Grant Name Agency Number
Abramson Cancer Ctr-UPENN Defining the molecular mechanisms underlying BRCA2 and RAD51 PARP lesion processing
Women’s Health Research at Yale Illuminating the BRCA2 Molecular Route to Ovarian Cancer
American Cancer Society Institutional Grant Biochemical and Genetic Characterization of BRCA2 Sequence Variants ACS-IRG #58-012-55
Breast Cancer Alliance, INC. (BCA) Biochemical and Genetic Characterization of BRCA2 Sequence Variants
Women's Health Research at Yale (WHRY) Biochemical Identification of "BRCAness" in Breast Cancer
Ovarian Cancer Research Fund A "Cellular Switch" to Modulate BRCA2-Mediated Tumor Progression
V Foundation Elucidating the Replication Fork Protection Problem Caused by PARP inhibitors in BRCA2-mutated Ovarian Cancers
American Cancer Society-Research Scholar Grant Elucidating Cancer Risk in Homology-directed Repair Variants RSG-17-038-01-01-DMC

Current Grants

Agency Grant Name Agency Number
NIH/NCI Elucidating Cancer Risk in BRCA2 and RAD51 Variants R01 CA215990
Gray Foundation Targeting the BRCA-dependent DNA repair axis for cancer therapy
University of Massachusetts/NIH/NCI Defining BRCA replication dysfunction in therapy response R01CA254037
Yale Cancer Center, 2022 Team Challenge Award

Expanding and improving DNA repair-focused therapies towards better breast cancer treatment

Project 2: Expanding and improving DNA repair-focused therapies towards better breast cancer treatment

NIH/NIEHS Collaborative Functions of BRCA2 and RAD51 Paralogs in Homologous recombination 1R21ES034164-01
NIH/NCI Defining the roles of BRCA2 and RAD51 in PARPi response 1R01CA270788-01

Henry Park

Current Grants

Agency Grant Name Agency Number
Food and Drug Administration Yale Mayo Clinic FDA Center of Excellence in Regulatory Science and Innovation Trends in Opioid Use Among Patients with Cancer Project U01 FD005938

Abhijit Patel

Past Grants

Agency Grant Name Agency Number
ASTRO Ultrasensitive Measurement of Tumor DNA in Blood as a Biomarker of Radiation Response JF2011-2
YCCI Circulating Tumor-Derived DNA as a Biomarker for Cancer Treatment Response 5 UL RR024139-05
Brozman Foundation Next-Generation Sequencing for Early Detection of Ovarian Tumor DNA in Blood
American Cancer Society Assessing Cancer Treatment Response by Measurement of Circulating Tumor-Derived DNA
YCC Tumor-Derived Circulating Mutant K-ras DNA as a Biomarker for Radiation Response: A Novel Deep Sequencing Approach
YCCI TARE Tumor DNA in Blood as a Biomarker for Early Detection and Monitoring of Lung Cancer
YCCI - Just-in time Small Pilot Grants Utilizing Core Technologies Tumor DNA in Blood as a Biomarker for Early Detection and Monitoring of Lung Cancer
YCC Pilot Early Detection of New or Recurrent Ovarian Cancer Using Mutant Tumor DNA in Blood
LUNGevity Detection of Early-Stage Lung Cancers via Tumor DNA in Blood
Yale SPORE in Lung Cancer Non-invasive monitoring of mutations in lung cancer via circulating tumor DNA
The Honorable Tina Brozman Foundation Early Detection of Ovarian Cancer via Analysis of Genomic Alterations in DNA & RNA from Multiple Sources of Blood
Department of Defense Early Detection of Lung Cancer via Tumor DNA Fragments in Blood W81XWH-16-1-0184
Breast Cancer Alliance, Inc. Profiling of Circulating Tumor Cells to Identify Targets for Adjuvant Therapy in Metastatic Triple Negative Breast Cancer
Yale Center for Genome Analysis Ultrahigh-Confidence Genomic and Epigenomic Sequencing at Single Cell Resolution
Honorable Tina Brozman Foundation Integrated Analysis of Proteomic and Genomic Signatures in Blood for for Early Detection of Ovarian Cancer
NIH/NCI Circulating DNA as a Marker of Treatment Efficacy and Failure in Lung Cancer 1 R01 CA197486-01A1

Current Grants

Agency Grant Name Agency Number
NIH/NCI Lung Cancer Screening via Ultrasensitive and Cost-efficient Analysis of Tumor DNA Signatures in Blood U01 CA233364

Faye Rogers

Agency Grant Name Agency Number
NIH Altered Helical Structures: Repair and Induction of Genomic Instability 5 K22 CA120049-03
NIH Altered Helical Structures: Repair STIMULUS FUNDS 3 K22 CA120049-03S1
Breast Cancer Alliance, INC. (BCA) Gene Targeted Apoptosis as a Therapeutic Strategy for HER2-Positive Breast Cancer 278479
YCCC Pilot Novel Therapeutic Strategy for the Treatment of Herceptin Resistant Breast Cancers
NIH/NCI Role of XPD in DNA Damage Response Pathway Choice R01 GM126211
NIH/NCI Gene-Targeted Apoptosis as a Treatment for HER2- Positive Breast Cancer 1 R21 CA185192-01A1
Amgen Foundation Yale BioMed SURF/Amgen Scholars Program: An Undergraduate Summer Research Program in Science and Biotechnology
Yale Cancer Center, Pilot Grant Therapeutic Targeting of Gene Amplification in High-Grade Serous Ovarian Cancer
Blavatnik Fund for Innovation at Yale Target Gene Therapeutics: Direct Targeting of Amplified Cancer Driver Genes as a Therapeutic Strategy

Lynn Wilson

Agency Grant Name Agency Number
NCI Racial Disparities in Clinical Outcomes and the Therapeutic Use of Radiotherapy for Patients with Cutaneous Lymphoma 1 R03 CA151153-01
Stanford Contract A Multicancer, Open-Label, Radomized, Phase I/II Study Evaluating the Safety and Efficacy of Low-Dose (12Gy)Total Skin Electron Beam Therapy (TSEBT) Combined with Verinostat versus Low Dose TSEBT Monotherapy in Mycosis Fungodes (MF) 27136490-50891-B